Galimedix Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
Galimedix is a clinical stage US/EU ophthalmic and CNS company developing truly novel & transformative small molecule treatments based on a novel MOA directed to the common cause of many neurodegenerative diseases.
Galimedix is looking for Series B/crossover financing to progress their assets to clinical proof of concept in glaucoma and Alzheimer´s disease. A NASDAQ IPO is planned for 2026/27, depending on overall market conditions.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}